The FDA cleared an investigational new drug application for OpCT-001, an investigational cell therapy for the treatment of primary photoreceptor diseases, according to a press release from BlueRock Therapeutics.
“We believe that, if approved, OpCT-001 has potential as a treatment for people living with primary photoreceptor diseases, which are a subgroup of inherited retinal disorders that includes retinitis pigmentosa and cone-rod dystrophy,” Amit Rakhit, MD, MBA, chief development and medical officer at BlueRock Therapeutics, told Healio. “Currently, no treatment options